SCHEMBL369986

SCHEMBL369986

CCCCCN(O)C=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9387988 0.98 ADH1C (0.48)
SCHEMBL1246938 0.92
Glyoxylate SCHEMBL8522137 0.89 HDAC2 (0.41)
SCHEMBL1247085 0.81
Fosmidomycin SCHEMBL14485270 0.74 S1PR2 (0.50)
SCHEMBL97181 0.74 ADH1C (0.48)
SCHEMBL2361603 0.74 ADH1C (0.48)
SCHEMBL3962903 0.72 ADH1C (0.52)
SCHEMBL2007141 0.72
SCHEMBL95389 0.72 ADH1C (0.52)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9533979-B2 Amino-derivatives as novel inhibitors of histone deacetylase JANSSEN PHARMACEUTICA NV (BE) 2017-01-03 US claimed
JP-4789927-B2 2011-10-12 JP claimed
US-20110092447-A1 USING INHIBITORS OF HISTONE DEACETYLASES FOR THE SUPPRESSION THERAPY OF INHERITED DISEASE PREDISPOSING CONDITIONS HENTSCH BERND 2011-04-21 US claimed
US-7892833-B2 Using inhibitors of histone deacetylases for the suppression therapy of inherited disease predisposing conditions TOPOTARGET GERMANY AG (DE) 2011-02-22 US claimed
WO-2010123507-A1 TREATMENT OF NON-LOCALIZED INFLAMMATION WITH PAN-HDAC INHIBITORS PHARMACYCLICS, INC. (US) 2010-10-28 WO claimed
EP-2001458-B1 USE OF VALPROIC ACID FOR THE TOPICAL TREATMENT OF MILD TO MODERATE ACNE VULGARIS TOPOTARGET GERMANY AG (DE) 2010-08-11 EP claimed
US-20090270497-A1 Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors PHARMACYCLICS, INC. (US) 2009-10-29 US claimed
US-20090186809-A1 USE OF VALPROIC ACID FOR THE TOPICAL TREATMENT OF MILD TO MODERATE ACNE VULGARIS TOPOTARGET GERMANY AG (DE) 2009-07-23 US claimed
EP-2039355-A2 Topical use of valproic acid for the prevention or treatment of skin disorders TopoTarget Germany AG (DE) 2009-03-25 EP claimed
US-20080318923-A1 1,3-Dihydro-2H-Indole-2-One Compound and Pyrrolidine-2-One Compound Fused With Aromatic Heterocycle TAISHO PHARMACEUTICAL CO., LTD. (JP) 2008-12-25 US claimed
US-20070037738-A1 Using Inhibitors of Histone Deacetylases for the Suppression Therapy of Inherited Disease Predisposing Conditions TOPOTARGET GERMANY AG (DE) 2007-02-15 US claimed
WO-2007009539-A2 USE OF INHIBITORS OF HISTONE DEACETYLASES IN COMBINATION WITH NSAID FOR THE THERAPY OF CANCER AND/OR INFLAMMATORY DISEASES TOPOTARGET GERMANY AG (DE) 2007-01-25 WO claimed
EP-1743654-A1 Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases TopoTarget Germany AG (DE) 2007-01-17 EP claimed
US-20060160897-A1 Topical Use of Valproic Acid for the Prevention or Treatment of Skin Disorders TOPOTARGET GERMANY AG (DE) 2006-07-20 US claimed
EP-1635808-A1 TOPICAL USE OF VALPROIC ACID FOR THE PREVENTION OR TREATMENT OF SKIN DISORDERS TopoTarget Germany AG (DE) 2006-03-22 EP claimed
EP-1635798-A2 INHIBITORS OF HISTONE DEACETYLASES FOR THE SUPPRESSION THERAPY OF DISEASES TopoTarget Germany AG (DE) 2006-03-22 EP claimed
WO-2005105055-A1 FORMULATION COMPRISING HISTONE DEACETYLASE INHIBITORS TOPOTARGET GERMANY AG (DE) 2005-11-10 WO claimed
EP-1591109-A1 Formulation comprising histone deacetylase inhibitor exhibiting biphasic release G2M Cancer Drugs AG (DE) 2005-11-02 EP claimed
WO-2005000282-A2 INHIBITORS OF HISTONE DEACETYLASES FOR THE SUPPRESSION THERAPY OF DISEASES TOPOTARGET GERMANY AG (DE) 2005-01-06 WO claimed
WO-2005000289-A1 TOPICAL USE OF VALPROIC ACID FOR THE PREVENTION OR TREATMENT OF SKIN DISORDERS TOPOTARGET GERMANY AG (DE) 2005-01-06 WO claimed